Transgenic News and Research

RSS

Conference to discuss frontline of immunological research, its clinical application

The immune system is evolved to protect our body against a variety of infectious agents which can cause serious and often fatal diseases. We now appreciate that the immune system is also involved in surveillance of malignant transformation of normal cells that constitute our body, as well as rejection of transplanted organs.

17 Sep 2010

Researchers synthesize new compounds to reduce A-beta 42 peptide in Alzheimer's disease

A team of scientists, led by University of California, San Diego School of Medicine researchers, has synthesized hundreds of new compounds with the potential of reducing the production of the A-beta 42 peptide, a primary component of Alzheimer's disease (AD).

9 Sep 2010

NGP 555 compound effective in preventing amyloid pathology of Alzheimer's disease

In the Sept. 9, 2010 issue of Neuron, Neurogenetic Pharmaceuticals, Inc. (NGP) reports proof of concept studies that show its proprietary compound, NGP 555, is effective in preventing the amyloid pathology of Alzheimer's disease (AD) in a transgenic mouse model.

8 Sep 2010

Scientists develop direct method to detect gene doping

Scientists at the universities in Tübingen and Mainz have developed a test that can provide conclusive proof of gene doping. "For the first time, a direct method is now available that uses conventional blood samples to detect doping via gene transfer and is still effective if the actual doping took place up to 56 days before," Professor Perikles Simon, MD, PhD from Johannes Gutenberg University Mainz, Germany explained on Thursday.

3 Sep 2010

'Sprouty' protein linked to regulation of bone mass and body fat

Here's good news for anyone trying to lose weight or has osteoporosis: Scientists from Maine are on the trail of a weight loss drug that may revolutionize how we treat these two conditions. In a new research report published in the September 2010 print issue of The FASEB Journal, the researchers describe a newly discovered protein, called "Sprouty," responsible for regulating body fat and bone mass. Then they manipulated how much of this protein was expressed in different groups of mice specially bred to have some human genes.

2 Sep 2010

Research on adult mammary stem cells may help to cure breast cancer

For the first time, researchers at Fred Hutchinson Cancer Research Center have identified and isolated adult mammary stem cells in mice. Long-term implications of this research may include the use of such cells to regenerate breast tissue, provide a better understanding of the role of adult stem cells in breast cancer development, and develop potential new targets for anti-cancer drugs.

2 Sep 2010

UBC researchers lead development of new 'toolbox of MiniPromoters' for gene research and therapy

University of British Columbia researchers have led the development of a new "toolbox of MiniPromoters" for research and future therapies on brain, spinal cord and eye function.

31 Aug 2010

Study supports role for SNARK protein in regulating glucose transport during muscle contraction and exercise

Skeletal muscles combust both lipids and carbohydrates during exercise. The carbohydrates consist of both glycogen stored in the muscles as well as glucose extracted from the blood. Being a major sink for glucose disposal, skeletal muscle represents an important model tissue for studying the intracellular signaling pathways leading to increased glucose transport.

21 Aug 2010

Jackson Laboratory to implement HighRes automated process for genotyping of laboratory mice

A highly accurate, automated process for managing the genotyping of laboratory mice is headed to Bar Harbor, Maine. In response to the increased demand for using transgenic mouse models and the requisite genotyping of such animals, The Jackson Laboratory will be implementing a HighRes Biosolutions automated process to improve the maintenance of their extensive and diverse mouse colonies.

17 Aug 2010

Down the silk road of the future

The Science paper notes that the development of silk hydrogels, films, fibers and sponges is making possible advances in photonics and optics, nanotechnology, electronics, adhesives and microfluidics, as well as engineering of bone and ligaments. Because silk fiber formation does not rely on complex or toxic chemistries, such materials are biologically and environmentally friendly, even able to integrate with living systems.

30 Jul 2010

Also in Global Health News: WHO reacts to Amnesty's N. Korea report; Universal flu vaccine; Malaria-resistant mosquitoes

The WHO is questioning the validity of the findings of a recent Amnesty International report which highlighted the dire needs of North Korea's health system, "contradict[ing] the rosier picture given by WHO chief Margaret Chan after her April trip there," the Associated Press reports. Although WHO spokesman Paul Garwood "insisted he wasn't criticizing Amnesty's work … he said Thursday's report was anecdotal, with stories dating back to 2001," which "[h]e contrasted … with WHO's science-based approach" (7/16).

17 Jul 2010

QR Pharma to present positive clinical data from mechanism of action study in MCI at ICAD 2010

QR Pharma, Inc., a developer of novel drugs to treat Alzheimer's disease (AD), is presenting a poster today on positive clinical data from its recent mechanism of action study in mild cognitive impaired (MCI) patients at the International Congress on Alzheimer's Disease (ICAD 2010).

15 Jul 2010

Plexxikon announces promising preclinical data of PLX3397

Plexxikon Inc. today announced promising preclinical data from in vivo Alzheimer's Disease studies demonstrating a dramatic reduction in activated microglia in the brains of very old (22 months) 3xTG-AD mice, a triple transgenic model for Alzheimer's Disease. This reduction of activated microglia led to significantly improved learning in the treated group.

15 Jul 2010

Pre-clinical study results of EVP-0015962 presented at AAICAD 2010

EnVivo Pharmaceuticals today announced at the Alzheimer's Association 2010 International Conference on Alzheimer's Disease results from its proprietary gamma-secretase modulator pre-clinical study. In a transgenic mouse model, EnVivo's EVP-0015962 reduced amyloid plaque buildup which is believed to be a cause of Alzheimer's disease, reversed behavioral deficits and reduced brain inflammation associated with Alzheimer's disease.

15 Jul 2010

New research studies presented at Alzheimer's Association International Conference

The primary therapeutic target in Alzheimer's disease has been the beta amyloid peptide, which clusters outside cells in the brain to form sticky clumps known as plaques. Recently, more attention has been given to the tau protein, which aggregates inside the brain cells of people with Alzheimer's, forming neurofibrillary tangles. Precisely how these proteins interact in causing the disease is unclear.

14 Jul 2010

GWAS suggests genetic variant with increased oncogene expression for cancer study

The study, published July 13th in Genome Research, showcases a new protocol for studying the activity of cancer-risk variants suggested by GWAS studies. The results also underscore the dramatic consequences of small genetic changes even in the vast stretches of DNA, known as "gene deserts," that do not code for proteins.

13 Jul 2010

Studies support association of physical activity, diet with maintaining cognitive ability, reducing dementia risk

Evidence from three long-term, large-scale studies supports the association of physical activity and certain dietary elements (tea, vitamin D) with possibly maintaining cognitive ability and reducing dementia risk in older adults, according to new research presented today at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 in Honolulu, HI.

12 Jul 2010

Alzheimer's Association recognizes four scientists for achievements in Alzheimer research at AAICAD 2010

The Alzheimer's Association recognized four scientists for their extraordinary achievements in advancing Alzheimer research at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 in Honolulu, Hawaii.

12 Jul 2010

Jasmine can be used instead of sleeping pills or mood enhancers: Study

Instead of a sleeping pill or a mood enhancer, a nose full of jasmine from Gardenia jasminoides could also help: in collaboration with Dr. Olga Sergeeva and Prof. Helmut Hass from the Heinrich Heine University in Düsseldorf, researchers from Bochum led by Prof. Dr. Dr. Dr. Hanns Hatt have discovered that the two fragrances Vertacetal-coeur (VC) and the chemical variation (PI24513) have the same molecular mechanism of action and are as strong as the commonly prescribed barbiturates or propofol.

9 Jul 2010

Alnylam Pharmaceuticals initiates dosing in Phase I human clinical study with ALN-TTR01

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it has initiated dosing in a Phase I human clinical study with ALN-TTR01. The study is aimed at evaluating the safety and tolerability of ALN-TTR01 in patients with transthyretin -mediated amyloidosis, and is also designed to provide preliminary data on human proof of concept based on measurements of TTR serum levels.

7 Jul 2010

Transgenic News and Research

Conference to discuss frontline of immunological research, its clinical application

Researchers synthesize new compounds to reduce A-beta 42 peptide in Alzheimer's disease

NGP 555 compound effective in preventing amyloid pathology of Alzheimer's disease

Scientists develop direct method to detect gene doping

'Sprouty' protein linked to regulation of bone mass and body fat

Research on adult mammary stem cells may help to cure breast cancer

UBC researchers lead development of new 'toolbox of MiniPromoters' for gene research and therapy

Study supports role for SNARK protein in regulating glucose transport during muscle contraction and exercise

Jackson Laboratory to implement HighRes automated process for genotyping of laboratory mice

Down the silk road of the future

Also in Global Health News: WHO reacts to Amnesty's N. Korea report; Universal flu vaccine; Malaria-resistant mosquitoes

QR Pharma to present positive clinical data from mechanism of action study in MCI at ICAD 2010

Plexxikon announces promising preclinical data of PLX3397

Pre-clinical study results of EVP-0015962 presented at AAICAD 2010

New research studies presented at Alzheimer's Association International Conference

GWAS suggests genetic variant with increased oncogene expression for cancer study

Studies support association of physical activity, diet with maintaining cognitive ability, reducing dementia risk

Alzheimer's Association recognizes four scientists for achievements in Alzheimer research at AAICAD 2010

Jasmine can be used instead of sleeping pills or mood enhancers: Study

Alnylam Pharmaceuticals initiates dosing in Phase I human clinical study with ALN-TTR01

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News